Enacts provisions relating to insurance coverage of health care services

Summary

The bill would stop health carriers and pharmacy‑benefits managers from penalizing doctors, patients, or pharmacies for providing medically necessary clinician‑administered drugs, biosimilars, or 340B‑priced medicines. It applies to any situation where the drug is covered but the insurer tries to limit payment, increase cost‑sharing, or otherwise interfere with access. The goal is to ensure consistent insurance coverage regardless of where the drug is obtained.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share